Kilitch Drugs (India)
KILITCH · NSEValuation
Blended fair value using DCF and peer comparison methods.
Peer comparison
How this company stacks up against sector peers on valuation and quality metrics.
Pharmaceuticals · 8 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
Kilitch Drugs (India) KILITCH · you | ₹589 Cr | 19.5× | 2.1× | 18.5× | 10.8% | 12.8% | 19.0% |
| Sector median | — | 30.7× | 4.1× | 23.6× | 13.8% | 14.5% | 11.0% |
| Neuland Laboratories NEULANDLAB | ₹22,034 Cr | 60.6× | 11.8× | 38.6× | 19.4% | 18.0% | 19.3% |
| Pfizer PFIZER | ₹21,129 Cr | 29.1× | 5.0× | 24.7× | 17.2% | 28.7% | 1.3% |
| Piramal Pharma PPLPHARMA | ₹19,898 Cr | — | 2.7× | 33.4× | -4.0% | -3.7% | 7.8% |
| Eris Lifesciences ERIS | ₹19,020 Cr | 30.2× | 4.8× | 18.1× | 15.9% | 19.8% | 22.9% |
| Granules India GRANULES | ₹18,955 Cr | 31.3× | 3.7× | 16.4× | 11.7% | 11.1% | 5.9% |
| Onesource Specialty Pharma ONESOURCE | ₹18,447 Cr | — | 3.4× | 64.6× | -1.3% | -5.2% | 232.4% |
| Syngene International SYNGENE | ₹18,242 Cr | 56.5× | 3.7× | 20.2× | 6.5% | 8.5% | 5.4% |
| Caplin Point Laboratories CAPLIPOINT | ₹17,160 Cr | 25.1× | 4.5× | 22.6× | 17.9% | 29.3% | 14.2% |
Kilitch trades at a discount to sector peers on P/E (19.5× vs median 30.7×). This may signal undervaluation — or reflect lower expected growth or higher perceived risk versus the peer group.
Business quality
Key profitability, efficiency, and solvency metrics.
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.
How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.